Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.12 USD | +0.52% | -1.18% | -19.57% |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
05-01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.57% | 80.78B | |
+31.03% | 662B | |
+21.96% | 546B | |
-5.26% | 359B | |
+17.01% | 323B | |
+4.70% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+4.07% | 167B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Market Chatter: Gilead Sciences Lawsuit Over COVID-19 Drug Remdesivir Dismissed by Russian Court